These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 34492161)

  • 1. Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
    Dimopoulou D; Spyridis N; Vartzelis G; Tsolia MN; Maritsi DN
    Arthritis Rheumatol; 2022 Feb; 74(2):365-366. PubMed ID: 34492161
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
    Brunelli JB; Silva CA; Pasoto SG; Saa CGS; Kozu KT; Goldenstein-Schainberg C; Leon EP; Vendramini MBG; Fontoura N; Bonfa E; Aikawa NE
    Clin Rheumatol; 2020 Feb; 39(2):515-521. PubMed ID: 31707543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
    Dimopoulou D; Vartzelis G; Dasoula F; Tsolia M; Maritsi D
    Ann Rheum Dis; 2022 Apr; 81(4):592-593. PubMed ID: 34844930
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.
    Weiss PF; Xiao R; Brandon TG; Pagnini I; Wright TB; Beukelman T; Morgan-DeWitt E; Feudtner C
    J Rheumatol; 2018 Jan; 45(1):107-114. PubMed ID: 28916542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12-15 years.
    King H; Deshpande S; Woodbridge T; Hilliard T; Standing J; Lewis M; Ward L; Finn A; Roderick M
    Arch Dis Child; 2022 Feb; 107(2):205-207. PubMed ID: 34446440
    [No Abstract]   [Full Text] [Related]  

  • 8. Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.
    Nicolai R; Cortis E; Ravà L; Bracaglia C; Pardeo M; Insalaco A; Buonuomo PS; Tozzi AE; De Benedetti F
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):76-9. PubMed ID: 26908493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
    Zhou M; Xu R; Kaelber DC; Gurney ME
    PLoS One; 2020; 15(3):e0229819. PubMed ID: 32203525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
    Khraishi M; Millson B; Woolcott J; Jones H; Marshall L; Ruperto N
    Pediatr Rheumatol Online J; 2019 Sep; 17(1):64. PubMed ID: 31500631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Variants and Therapeutic Response to Anti-TNF-α Agents in Juvenile Idiopathic Arthritis: An Updated Systematic Review and Meta-analysis.
    Pregnolato F; Chighizola CB; Giani T; Costi S; Marino A; Cimaz R
    J Clin Rheumatol; 2022 Oct; 28(7):374-378. PubMed ID: 35777854
    [No Abstract]   [Full Text] [Related]  

  • 14. Refractory systemic juvenile idiopathic arthritis successfully treated with rapamycin.
    Concha S; Rey-Jurado E; Poli MC; Hoyos-Bachiloglu R; Borzutzky A
    Rheumatology (Oxford); 2021 Jul; 60(7):e250-e251. PubMed ID: 33547778
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the true incidence of COVID-19 in patients with rheumatic diseases?
    Favalli EG; Ingegnoli F; Cimaz R; Caporali R
    Ann Rheum Dis; 2021 Feb; 80(2):e18. PubMed ID: 32321723
    [No Abstract]   [Full Text] [Related]  

  • 16. Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.
    Marino A; Romano M; Gattinara M; Cimaz R
    Semin Arthritis Rheum; 2020 Dec; 50(6):1214-1215. PubMed ID: 33059294
    [No Abstract]   [Full Text] [Related]  

  • 17. The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis.
    Bašić J; Vojinović J; Jevtović-Stoimenov T; Despotović M; Cvetković T; Lazarević D; Sušić G; Milošević V; Cvetković M; Pavlović D
    Rheumatol Int; 2019 Mar; 39(3):551-559. PubMed ID: 30680511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept.
    Öman A; Dicksved J; Engstrand L; Berntson L
    Pediatr Rheumatol Online J; 2021 Apr; 19(1):55. PubMed ID: 33902613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
    Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
    Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.